Biogen Inc. Receives FDA Breakthrough Therapy Designation for Felzartamab, A Key Value Stock for Investors

Biogen FDA Breakthrough Therapy Designation Biogen Inc. (Nasdaq: BIIB), a leading biotechnology company, announced today that its investigational anti-CD38 monoclonal antibody, felzartamab,…